Literature DB >> 1184723

Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate.

M R Stjernholm, F H Katz.   

Abstract

The metabolic clearance rates (MCR) of methylprednisolone (MP) (no. = 13) and methylprednisolone-21- Na-hemisuccinate (MPHS) (no. = 6) were studied in normal humans using tritium-labeled steroids. The cumulative appearance of the labeled steroid was examined for the whole urine and for three major urinary fractions. The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS. Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001). Similar effects were found with phenobarbital (PB). Diazepam (DZP) had no effect. Major increases in urinary metabolites after DPH and PB were in the unconjugated ethyl acetate fraction, and this suggests that MP metabolism is significantly altered by hepatic microsomal hydroxylation enzyme induction by DHP and PB, but not DZP. This could occur with the formation of a 6beta-hydroxy derivative which could be readily cleared by the kidney. The urinary pattern of excretion for MPHS was similar to that of MP. The MCR of MPHS was affected to a lesser extent by DPH and PB than was the MCR of MP(P less than 0.01). Therefore, the use of hepatic microsomal hydroxylase inducers should be taken into consideration in clinical states in which MP is being used.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184723     DOI: 10.1210/jcem-41-5-887

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Alterations of glucocorticoid actions by other drugs and disease states.

Authors:  W Jubiz; A W Meikle
Journal:  Drugs       Date:  1979-08       Impact factor: 9.546

Review 3.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 4.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

Review 5.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

6.  Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.

Authors:  J Q Rose; A M Yurchak; A W Meikle; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

9.  High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.

Authors:  P J Hayball; D G Cosh; M J Ahern; D W Schultz; P J Roberts-Thomson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 10.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.